Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer

Summary

At present, there are no relevant studies or reports on the effect of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer. Studied in this paper combin neoadjuvant chemoradiation with immune therapy, carry out "Multicenter prospective randomized clinical trial of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer" in order to provide a high-level evidence-based medical evidence for ultra-low rectal cancer treatment and improve ultra-low rectal cancer diagnosis and treatment effect.

Timeline

Start

2022-10-01

Primary completion

2024-12-30

Completion

2025-06-24

Publications

• Zhou L, Yu G, Wen R, Jia H, Zhang T, Peng Z, Fan H, Pan A, Yu Y, Zhu X, Gong H, Gao X, Lou Z, Zhang W. Neoadjuvant chemoradiation therapy combined with immunotherapy for microsatellite stable ultra-low rectal cancer (CHOICE II): study protocol of a multicentre prospective randomised clinical trial. BMJ Open. 2023 Sep 13;13(9):e069793. doi: 10.1136/bmjopen-2022-069793.

Drugs

Indications